MARKSANS PHARMA LIMITED Fair Value
MARKSANS · Healthcare · Current price ₹329.25
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹70 | 15% ROE fading to 12% over ~3 yrs, on ₹67 book |
| Relative P/E | ₹280 | EPS × 30.3 peer-median P/E |
| Graham floor | ₹118 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹294 | Street consensus 12-month target price |
Is MARKSANS PHARMA LIMITED undervalued?
DocStoX estimates the fair value of MARKSANS PHARMA LIMITED at ₹165 per share, versus the current market price of ₹329. That puts the stock about -49.9% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹70), Relative P/E (₹280), Graham floor (₹118), Analyst target (₹294). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹70 (bear) to ₹165 (base) to ₹294 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on MARKSANS PHARMA LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.